Polyendocrine Metabolic Ovarian Syndrome Epidemiology

• According to DelveInsight’s analysis, the PMOS diagnosed prevalent cases were found to be ~20 million in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• The evolving understanding of PMOS as a multisystem condition involving hormonal imbalance, metabolic dysfunction, fertility impairment, and increased long-term risks of diabetes and cardiovascular complications is expected to drive greater disease awareness and healthcare attention.
• Among the EU4 and the UK, Germany had the highest (~25%) number of diagnosed prevalent cases of PMOS, followed by UK, while Spain reported the lowest cases.
• Growing awareness of the disease burden, diagnostic challenges, and long-term metabolic consequences may support expansion of research initiatives.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of PMOS: ~20 million Cases 
• 2036 Projected Diagnosed Prevalent Cases of PMOS: ~XX million Cases
• PMOS Growth Rate (2026–2036): ~3% CAGR

DelveInsight's ‘Polyendocrine Metabolic Ovarian Syndrome (PMOS) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the PMOS, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Understanding and Diagnosis Algorithm

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Overview

Polycystic Ovary Syndrome (PCOS), officially renamed as PMOS in 2026, is one of the most common endocrine and metabolic disorders affecting women of reproductive age. The new terminology more accurately reflects the multisystem nature of the disease, recognizing that it extends beyond the ovaries and that many affected individuals do not have polycystic ovaries. PMOS is characterized by a complex interaction of hormonal imbalance, insulin resistance, chronic low-grade inflammation, and ovarian dysfunction, leading to hyperandrogenism, ovulatory dysfunction, and variable ovarian morphology. In addition to reproductive complications such as infertility and menstrual irregularities, the disorder is associated with obesity, T2D, dyslipidemia, hypertension, metabolic dysfunction-associated steatotic liver disease (MASLD), and psychological disorders, including anxiety and depression. Owing to its lifelong clinical burden, high prevalence, and broad metabolic implications, PMOS remains a significant public health challenge with substantial unmet medical needs, particularly given the absence of disease-specific approved therapies.

Further details are provided in the report.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Diagnosis

The diagnosis of PMOS, is based on a combination of clinical, biochemical, and imaging findings, as no single diagnostic test exists. The Rotterdam criteria remain the most widely accepted diagnostic standard, requiring the presence of at least two of the following after excluding other endocrine disorders: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. A comprehensive evaluation includes assessment of serum androgen levels, thyroid function, prolactin, and adrenal hormones to rule out alternative causes of menstrual irregularities and androgen excess. Given the syndrome's strong metabolic component, patients are also routinely screened for obesity, insulin resistance, impaired glucose tolerance or T2D, dyslipidemia, hypertension, and other cardiometabolic risk factors to guide long-term management.

Further details are provided in the report.

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Epidemiology

Key Findings from Polyendocrine Metabolic Ovarian Syndrome (PMOS) Epidemiological Analysis and Forecast 

• According to DelveInsight estimates, there were approximately 20 million diagnosed prevalent cases of PMOS in the 7MM in 2025. 
• Among the 7MM, US had the highest number of diagnosed prevalent cases, at around 9.4 million cases.
• Among the age-specific segment, the age group 26–35 had the highest (~45%) number of cases followed by the age group of 36–49 in the US in 2025.
• As per clinical manifestations, polycystic ovaries had the highest number of cases followed by hyperandrogenem in Japan in 2025.

Scope of the Report

• The report covers a segment of a descriptive overview of PMOS, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Polyendocrine Metabolic Ovarian Syndrome (PMOS) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by Geography)

FAQs

• What are the disease risks, burdens, and unmet needs of PMOS? What will be the growth opportunities across the 7MM concerning the patient population with PMOS?
• What is the historical and forecasted PMOS patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.